头颈癌[18F]氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描分期的多中心试验及临床N0颈部的阴性预测值和手术影响:ACRIN 6685结果
该前瞻性多中心试验纳入287例新诊断头颈鳞癌患者,评估PET/CT对临床N0颈部的阴性预测值(NPV)。212例患者270侧N0颈部可评估,视觉评估NPV为0.868,预设SUVmax cutoff 2.5和3.5的NPV分别为0.940和0.937,最佳cutoff 1.8时NPV为0.942。PET/CT使22%患者手术计划改变,结论认为PET/CT对T2-T4 HNSCC的N0颈部有高NPV,可能辅助临床决策。
要点
- 视觉评估临床N0侧NPV为0.868(95%CI 0.803-0.925)。
- SUVmax cutoff 2.5和3.5的NPV分别为0.940和0.937,最佳cutoff 1.8时NPV为0.942。
- PET/CT使22%(51/237)患者手术计划改变,其中14%增加计划清扫淋巴结水平,5%减少。
核心结论
- [18F]氟脱氧葡萄糖-PET/CT对T2至T4头颈鳞癌的N0颈部具有高阴性预测值。
- 基于PET/CT发现的手术治疗计划在该组中约22%可能被改变。
- 这些发现提示[18F]氟脱氧葡萄糖-PET/CT可能辅助临床医生决定临床N0颈部头颈鳞癌的最佳治疗。
- 应开展设计良好的临床试验来验证通过PET/CT省略颈清扫的结果。
研究设计与样本
- 前瞻性多中心试验,自23家美国放射学院影像网络(ACRIN)合格机构纳入287例新诊断、首次、头颈鳞癌(HNSCC)且至少一侧临床N0颈部计划行颈清扫的参与者。
- PET/CT与颈清扫病理 findings 进行比较。
- 212例参与者的270侧N0颈部有可用的PET/CT扫描和病理结果。
主要发现
- 视觉评估时,针对临床N0侧的NPV为0.868(95%CI 0.803至0.925)。
- 针对淋巴结 basin 的二分最大标准化摄取值(SUVmax)NPV在预设cutoff 2.5和3.5时分别为0.940(95%CI 0.928至0.952)和0.937(95%CI 0.925至0.949)。
- 最佳cutoff SUVmax确定为1.8,NPV为0.942(95%CI 0.930至0.953)。
- 与PET/CT盲法手术计划相比,PET/CT知情的手术治疗计划在237例参与者中的51例(22%)发生改变。
- 在34例参与者(14%)中,这导致计划清扫额外淋巴结水平;在12例参与者(5%)中,这导致计划清扫淋巴结水平减少。
关键数值与推荐
- 临床N0侧的视觉评估NPV为0.868(95%CI 0.803至0.925)。
- 预设SUVmax cutoff 2.5时淋巴结 basin 的NPV为0.940(95%CI 0.928至0.952)。
- 预设SUVmax cutoff 3.5时淋巴结 basin 的NPV为0.937(95%CI 0.925至0.949)。
- 最佳cutoff SUVmax 1.8时NPV为0.942(95%CI 0.930至0.953)。
临床怎么用
- [18F]氟脱氧葡萄糖-PET/CT可能辅助临床医生决定临床N0颈部头颈鳞癌的最佳治疗。
- 基于PET/CT发现的手术治疗计划在该组中约22%可能被改变。
- 作者认为应开展设计良好的临床试验来验证通过PET/CT省略颈清扫的结果。
局限性
- 应开展设计良好的临床试验来验证通过PET/CT省略颈清扫的结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The objective of this study was to determine the negative predictive value (NPV) of positron emission tomography (PET)/computed tomography (CT) for the clinically N0 neck on the basis of neck dissection. METHODS: Participants with newly diagnosed, first-time, head and neck squamous cell carcinoma (HNSCC) and at least one clinically N0 neck side for which dissection was planned were included. A total of 287 participants were prospectively enrolled from 23 American College of Radiology Imaging Network-qualified institutions. PET/CT was compared with findings at neck dissection. RESULTS: PET/CT scans and pathology findings were available for 270 N0 neck sides from 212 participants. For visual assessment, the NPV specific to the clinical-N0 sides was 0.868 (95% CI, 0.803 to 0.925). For dichotomized maximum standardized uptake value, the NPVs specific to the nodal basins were 0.940 (95% CI, 0.928 to 0.952) and 0.937 (95% CI, 0.925 to 0.949) at prespecified cutoffs of 2.5 and 3.5, respectively. The optimal cutoff maximum standardized uptake value was determined to be 1.8, with an NPV of 0.942 (95% CI, 0.930 to 0.953). The PET/CT-informed surgical treatment plan was changed in 51 of 237 participants (22%) compared with the PET/CT-blinded surgical plan. In 34 participants (14%), this led to planned dissection of additional nodal levels. In 12 participants (5%), this led to fewer planned dissected nodal levels. Negative PET/CT scans in N0 necks was true negative in 87% and false negative in 13%. CONCLUSION: [18F]fluorodeoxyglucose-PET/CT has high NPV for the N0 neck in T2 to T4 HNSCC. The surgical treatment plans on the basis of PET/CT findings may be changed in approximately 22% of this group. These findings suggest that [18F]fluorodeoxyglucose-PET/CT may assist the clinician in deciding on the best therapy for the clinically N0 neck in HNSCC. Well-designed clinical trials should be performed to test the outcome of omitting neck dissection by using PET/CT.
引用
- Lowe VJ, Duan F, Subramaniam RM, et al. Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685. J Clin Oncol. 2019. PMID: 30768363. doi:10.1200/JCO.18.01182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。